Dr. Michael Lazar

Fewer men are being screened, diagnosed, and treated for prostate cancer

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

2018-05-22T15:07:32+00:00 May 22nd, 2018|

Who is the best candidate for HIFU prostate cancer treatment?

Is HIFU Prostate Cancer Treatment for You? High Intensity Focused Ultrasound (HIFU) is a FDA approved non-invasive therapy for treating prostate cancer. Find out if you qualify for HIFU. HIFU may not be appropriate in every situation, but it is most effective for men who have early stage, localized prostate cancer that has not spread or metastasized outside the prostate HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of [...]

2018-05-08T08:30:04+00:00 May 8th, 2018|

Wives of many prostate cancer sufferers challenged by the disease

Many wives of advanced prostate cancer sufferers feel that their lives are being undermined by their husband’s illness, with nearly half reporting that their own health suffered. In addition a focus subgroup has revealed that many feel isolated and fearful, and worry about the role change in their lives as their husband’s cancer advances. This study, developed with the wives of men with metastatic prostate cancer who were being treated with hormone therapy, is amongst the first carried out on how prostate cancer affects the partners of sufferers. It was presented yesterday at the EAU conference in Copenhagen. Prostate cancer is the most common male cancer. Prostate cancer which metastisises to other parts of the body is often difficult or impossible to cure, and [...]

2018-03-27T16:53:05+00:00 March 27th, 2018|

New roadmap developed to genetically test for hereditary prostate cancer

A roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer has been developed by a team of researchers. To date, there have been few recommendations to guide physicians about when to offer men genetic consultation for prostate cancer risk. Now, an international and inter-specialty panel of experts convened at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University have developed a comprehensive set of recommendations. This consensus statement, published December 13th in the Journal of Clinical Oncology, will help physicians and stakeholders make sense of a rapidly evolving field of practice. "There is increasing recognition that some prostate cancers can be inherited. Genetic testing could provide men and their families with information about cancer [...]

2018-01-09T08:50:54+00:00 January 9th, 2018|

#1 New Year’s Resolution for Men: Get screened for prostate cancer

#1 New Year’s Resolution for Men: Get screened for prostate cancer   Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options; says early detection saves lives. “Knowing the many options for treating prostate cancer is something all men at risk of developing the disease need to be informed about,” says Dr. Lazar. “Most men know about the unpleasant side effects that go along with traditional models of prostate cancer treatment, including urinary incontinence, bowel and erectile dysfunction. But some of the newer treatment modalities such as HIFU (high-intensity focused ultrasound) can only be undertaken at the early stages, when damage to surrounding tissue can best be mitigated, and most side effects eliminated.” Why Early [...]

2018-01-02T13:01:35+00:00 January 2nd, 2018|

CMS Announces Increase To ASC Payment For HIFU Prostate Ablation

SonaCare Medical Reports That Medicare recognizes HIFU prostate ablation as a device-intensive procedure driving new ASC payment going into effect on or after October 1, 2017 CHARLOTTE, N.C., Sept. 20, 2017 SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to announce an increase in Medicare payment for prostate HIFU ablation in the Ambulatory Surgical Center (ASC) setting. In the October 2017 update of the ASC Payment System, the Centers for Medicare and Medicaid Services (CMS) indicated that the ASC payment status for C9747, the code used to bill for HIFU ablation of prostate tissue, now recognizes HIFU as a "device-intensive procedure". The new typical ASC payment level is $5,444.89, as compared to the approximately $4,000 payment amount which went [...]

2017-12-13T13:37:18+00:00 November 14th, 2017|

Research News: Reduced Risk of Prostate Cancer in Men with Low Testosterone

Men with unusually low amounts of testosterone in their blood are around 20% less likely to develop prostate cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool. Scientists from the University of Oxford conducted the largest analysis of hormones and prostate cancer risk to date. The study – funded by Cancer Research UK – looked at blood samples from around 19,000 men aged 34-76 years, collected between 1959 and 2004. Of these men 6,900 went on to develop prostate cancer. The researchers divided the 19,000 men into ten groups – ranging from men with the lowest amount of testosterone in their blood to those with the highest, and compared their prostate cancer risk. They found that men [...]

2017-12-13T13:37:18+00:00 November 8th, 2017|

New study reveals: Regret is lasting for many men who undergo traditional prostate cancer treatments

Responding to a recent review of patient comments spanning two decades Dr. Michael Lazar of California HIFU talks about the importance of informing prostate cancer patients about all available treatment options. A recent study revealed this month that as they get older, some men who have undergone treatment for prostate cancer come to regret the treatment decisions they made. This study reviewed the survey results of 934 men conducted at intervals of one, two, five, and 15 years after they were treated for prostate cancer. Most of the men (89%) were treated with surgery or radiation. Ultimately, 14.6% of the entire group expressed some regret over treatment results (16.6% of the radiation-treated men, 15% of the surgically-treated men, and 8.2% of the men treated conservatively). [...]

2017-12-13T13:37:18+00:00 October 23rd, 2017|

New research could lead to reduction in recurrence of prostate cancer

Recurrence of prostate cancer could be reduced thanks to exciting new discovery Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports. During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer. Anti-hormone therapy is a commonly prescribed treatment for cancer of the prostate, which helps to reduce the levels of male hormones -- that stimulate cancer cells to grow -- in the gland. Researchers discovered that an inadvertent consequence of anti-hormone therapy treatment is the activation of the DNA repair enzyme, PARP. The triggering of PARP enables cancer cells to withstand anti-hormone therapy treatment, causing [...]

2017-12-13T13:37:18+00:00 October 17th, 2017|

Prostate Cancer News: PSA screening significantly reduces the risk for death

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would reduce [...]

2017-12-13T13:37:19+00:00 October 11th, 2017|